Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint

by Brian E. Lacy, Jean Paul Nicandro, Emil Chuang, David L. Earnest
Published 2018-05-01